NasdaqGS - Delayed Quote • USD
Compare
At close: September 3 at 4:00 PM EDT
After hours: September 3 at 6:33 PM EDT
Line
Candle
Baseline
Mountain
Bar
Loading Chart for AMGN
9/21 12:03 PM
DELL
Date | |
Close | |
Open | |
High | |
Low | |
Volume |
- Previous Close
333.83 - Open
331.59 - Bid 330.33 x 100
- Ask 330.81 x 100
- Day's Range
329.10 - 333.00 - 52 Week Range
248.38 - 346.85 - Volume
2,120,082 - Avg. Volume
2,074,891 - Market Cap (intraday)
177.593B - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
57.08 - EPS (TTM)
5.79 - Earnings Date Oct 29, 2024 - Nov 4, 2024
- Forward Dividend & Yield 9.00 (2.72%)
- Ex-Dividend Date Aug 16, 2024
- 1y Target Est
328.50
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
26,700
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Drug Manufacturers - General
Industry
More about Amgen Inc.
Recent News: AMGN
View MoreAll SEC Filings
Corporate Changes & Voting Matters
Periodic Financial Reports
Proxy Statements
Tender Offer/Acquisition Reports
Offering Registrations
Performance Overview: AMGN
Trailing total returns as of 9/3/2024, which may include dividends or other distributions. Benchmark is
YTD Return
AMGN
17.28%
S&P 500
15.91%
1-Year Return
AMGN
32.62%
S&P 500
22.44%
3-Year Return
AMGN
60.90%
S&P 500
21.86%
5-Year Return
AMGN
84.31%
S&P 500
88.93%
Compare To: AMGN
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
330.51
-0.99%
Mkt Cap 177.593B
Industry Drug Manufacturers—General
197.69
+0.70%
Mkt Cap 349.188B
Industry Drug Manufacturers—General
116.58
-1.58%
Mkt Cap 295.508B
Industry Drug Manufacturers—General
79.70
+0.89%
Mkt Cap 99.226B
Industry Drug Manufacturers—General
50.52
+1.14%
Mkt Cap 102.424B
Industry Drug Manufacturers—General
Mkt Cap 402.394B
Industry Drug Manufacturers—General
204.84
+0.04%
Mkt Cap 29.837B
Industry Drug Manufacturers—General
85.72
-2.17%
Mkt Cap 265.778B
Industry Drug Manufacturers—General
956.53
-0.36%
Mkt Cap 861.284B
Industry Drug Manufacturers—General
118.50
-1.98%
Mkt Cap 244.398B
Industry Drug Manufacturers—General
28.30
-2.45%
Mkt Cap 160.368B
Industry Drug Manufacturers—General
Statistics: AMGN
View More
Valuation Measures
As of 9/3/2024
Market Cap
177.69B
Enterprise Value
231.03B
Trailing P/E
57.02
Forward P/E
16.10
PEG Ratio (5yr expected)
2.28
Price/Sales (ttm)
5.77
Price/Book (mrq)
29.99
Enterprise Value/Revenue
7.47
Enterprise Value/EBITDA
19.56
Financial Highlights
Profitability and Income Statement
Profit Margin
10.12%
Return on Assets (ttm)
4.48%
Return on Equity (ttm)
49.27%
Revenue (ttm)
30.93B
Net Income Avi to Common (ttm)
3.13B
Diluted EPS (ttm)
5.79
Balance Sheet and Cash Flow
Total Cash (mrq)
9.3B
Total Debt/Equity (mrq)
1,057.30%
Levered Free Cash Flow (ttm)
3.01B
Research Analysis: AMGN
View MoreResearch Reports: AMGN
View MorePeople Also Watch
BIIB Biogen Inc.
204.84
+0.04%
GILD Gilead Sciences, Inc.
79.70
+0.89%
BMY Bristol-Myers Squibb Company
50.52
+1.14%
MRK Merck & Co., Inc.
116.58
-1.58%
LLY Eli Lilly and Company
956.53
-0.36%
ABT Abbott Laboratories
114.66
+1.23%
UNH UnitedHealth Group Incorporated
598.68
+1.44%
MDT Medtronic plc
88.96
+0.43%
JNJ Johnson & Johnson
167.16
+0.78%
ABBV AbbVie Inc.
197.69
+0.70%
REGN Regeneron Pharmaceuticals, Inc.
1,168.81
-1.34%
VRTX Vertex Pharmaceuticals Incorporated
475.70
-4.07%
PFE Pfizer Inc.
28.30
-2.45%
NVS Novartis AG
118.50
-1.98%
TXN Texas Instruments Incorporated
201.83
-5.84%
AMAT Applied Materials, Inc.
183.37
-7.04%